Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.

Madhav Prasad YadavSanjana BallalRanjit Kumar SahooMadhavi TripathiNishikant Avinash DamleShamim Ahmed ShamimRakesh KumarAmlesh SethChandrasekhar Bal

Published in: PloS one (2021)

The current study supports the short-term safety and efficacy results of high response rates, prolonged PFS and OS, improved quality of life, and low treatment-related toxicities in patients treated with 177Lu-PSMA-617 radioligand therapy.

Keyphrases

pet ct
end stage renal disease
newly diagnosed
ejection fraction
pet imaging
squamous cell carcinoma
chronic kidney disease
small cell lung cancer
peritoneal dialysis
stem cells
computed tomography
combination therapy
patient reported
positron emission tomography
cell therapy
smoking cessation